The current price of 4527.T is ¥2,696.00 — it has decreased by 5.54% since the previous close. Data as of Nov 6, 2026.
4527.T is down 1.96% over the past week, down 1.23% over the past month and up 11.54% over the past year. The price is above its 200-day moving average of ¥2,552.71.
Of the 11 analysts covering Rohto Pharmaceutical Co.,Ltd., 4 rate it a strong buy, 4 rate it a buy and 3 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Rohto Pharmaceutical Co.,Ltd. has a market capitalization of ¥609.2B. The company belongs to the Consumer Defensive sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Rohto Pharmaceutical Co.,Ltd. posted earnings of ¥47.14 per share against an estimate of ¥38.77, beating expectations by 21.59%. Upcoming reports are listed in the earnings calendar.
Rohto Pharmaceutical Co.,Ltd. reported revenue of ¥91.62B in its most recent quarter, which has increased by 11.79% compared with the same quarter a year earlier. Analysts had expected ¥87.05B.
Yes. Rohto Pharmaceutical Co.,Ltd. pays dividends semi-annually. The latest payment of ¥25.00 per share has a payment date of Mar 30, 2027, which corresponds to a dividend yield of 1.85%.
Companies most comparable to Rohto Pharmaceutical Co.,Ltd. include Kao Corporation, Shiseido Company, Limited, Yakult Honsha Co.,Ltd., Santen Pharmaceutical Co., Ltd. and Kobayashi Pharmaceutical Co., Ltd.
In the latest trading session 4527.T moved between ¥2,675.50 and ¥2,846.50, a range of 6.34% of its current price.
Over the past 52 weeks 4527.T has traded between ¥2,218.50 and ¥3,122.00. The current price is 13.65% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.